Débora Silva

Dr. Débora Silva

Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
SSStella Costa Silva
Stella Costa Silva
Débora SilvaDébora Silva
Débora Silva
TATamires Almeida
Tamires Almeida
FPFernanda Barçante Perasoli
Fernanda Barçante Perasoli
ASAndré Talvani Pedrosa da Silva
André Talvani Pedrosa da Silva
SRSimone Aparecida Rezende
Simone Aparecida Rezende

16 January 2018 in Pathology Research International
Verified
Journal Article
Open access
PDF file
TLTamara C. M. Lopes
Tamara C. M. Lopes
Débora SilvaDébora Silva
Débora Silva
WCWalyson C. Costa
Walyson C. Costa
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
JBJosé M. Barichello
José M. Barichello
SRSimone A. Rezende
Simone A. Rezende
Tartar emetic (TE) was the first drug used to treat leishmaniasis. However, its use was discontinued due to high toxicity. Association of TE with liposomes is a strategy to reduce its side effects. Pegylated liposomes (Lpeg) present lower rates of uptake by macrophages and prolonged circulation compared to their nonpegylated counterparts. However, repeated administration of Lpeg can cause an Accelerated Blood Clearance(ABC)phenomenon, whereby recognition of liposomes by antibodies results in faster phagocytosis. This work evaluated the effect of TE administration on histopathological aspects and the effect of theABCphenomenon on targeting and toxicity in mice. Our results show that treatment with free or liposomal TE had no effect on the erythrocyte count, on liver and spleen weight, and on hepatic, splenic, and cardiac histology in mice. Severe lesions were observed on the kidneys of animals treated with a single dose of free TE. Treatment with TE in Lpeg after induction ofABCphenomenon caused a significant increase in Sb level in the liver without toxicity. Furthermore, mice treated with TE in liposomes showed normal renal histopathology. These results suggest site-specific targeting of Sb to the liver after induction ofABCphenomenon with no toxicity to other organs.

10 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Débora SilvaDébora Silva
Débora Silva
LRLevi Eduardo Soares Reis
Levi Eduardo Soares Reis
MMMarina Guimarães Carvalho Machado
Marina Guimarães Carvalho Machado
DDDouglas Daniel Dophine
Douglas Daniel Dophine
VAVinicius Roberto de Andrade
Vinicius Roberto de Andrade
Vanessa Carla Furtado MosqueiraVanessa Carla Furtado Mosqueira
Vanessa Carla Furtado Mosqueira
Standards of care for human visceral leishmaniasis (VL) are based on drugs used parenterally, and oral treatment options are urgently needed. In the present study, a repurposing strategy was used associating tamoxifen (TMX) with polyethylene glycol-block-polylactide nanocapsules (NC) and its anti-leishmanial efficacy was reported in vivo. Stable surface modified-NC (5 mg/mL of TMX) exhibited 200 nm in size, +42 mV of zeta potential, and 98% encapsulation efficiency. Atomic force microscopy evidenced core-shell-NC. Treatment with TMX-NC reduced parasite-DNA quantified in liver and spleen compared to free-TMX; and provided a similar reduction of parasite burden compared with meglumine antimoniate in mice and hamster models. Image-guided biodistribution showed accumulation of NC in liver and spleen after 30 min post-administration. TMX-NC reduced the number of liver granulomas and restored the aspect of capsules and trabeculae in the spleen of infected animals. TMX-NC was tested for the first time against VL models, indicating a promising formulation for oral treatment.